Clinical Trials Directory

Trials / Completed

CompletedNCT00800852

Increased Expression of Adiponectin Receptor 2 in the Mononuclear Cells in Children With Prader-Willi Syndrome

Status
Completed
Phase
Study type
Observational
Enrollment
Sponsor
Samsung Medical Center · Academic / Other
Sex
All
Age
18 Years
Healthy volunteers
Accepted

Summary

The inflammatory process is involved in the pathogenesis of obesity. Prader-Willi syndrome (PWS) is a genetic model of syndromic obesity. Adiponectin is an adipokine with potent anti-inflammatory properties, and its effect is mediated through adiponectin receptors 1 (adipoR1) and 2 (adipoR2). Objective of this study is to compare the expression of adipoR1, adipoR2, and adiponectin in peripheral blood mononuclear cells (PBMCs) in PWS children and obese control and to correlate receptor expression with insulin sensitivity and obesity-related parameters.

Conditions

Timeline

First posted
2008-12-02
Last updated
2008-12-02

Source: ClinicalTrials.gov record NCT00800852. Inclusion in this directory is not an endorsement.